The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
Zacks.com on MSN6d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group ... bringing in more than $7.3 billion in “excess” revenue over six years, the Federal Trade Commission said in a report on ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback